Yes, GLP-1 Medications Really Do Reduce Alcohol Cravings, Per A New Study
Now, the growing buzz around the use of GLP-1 medications like Ozempic to treat alcohol use disorder finally has new clinical study results that support this theory. (Prior studies have simply found a link between taking a GLP-1 receptor agonist and drinking less—but didn’t go so far as to actually prove that the medications caused people to drink less.
Weight loss drug semaglutide may reduce alcohol cravings, heavy drinking and smoking, new study finds
Semaglutide, a medication widely used for diabetes and weight loss, may offer another unexpected benefit -- it could help people drink less alcohol.
New study offers hints of GLP-1 drugs’ potential in curbing alcohol cravings
A small semaglutide trial suggests the medicine's suppression of appetite may extend to alcohol, but larger tests are needed to establish a conclusive benefit.
Could obesity drugs help with alcohol cravings? New study suggests potential
A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.
Obesity drugs may help people drink less alcohol: Study
A new study suggests that using weight loss drugs such as Ozempic and Wegovy can lead to less alcohol consumption. The study, published Wednesday by JAMA Psychiatry, looked into 48 people the medical journal described as “non–treatment-seeking” participants who suffer from alcohol use disorder (AUD).
Ozempic can curb alcohol cravings, study finds
Semaglutide, the drug sold as Ozempic to treat type 2 diabetes and Wegovy for weight loss, reduced alcohol cravings and consumption in a small trial involving people with moderate alcohol use disorder,
FiercePharma2d
'We cannot stay silent': Novo Nordisk flags dangers of compounded GLP-1s following Hims & Hers Super Bowl ad
Telehealth company Hims & Hers stirred up controversy by debuting a 2025 Super Bowl ad touting the benefits of its ...
What Happens If I Stop Taking GLP-1s for Weight Loss?
If you’ve been using a GLP-1 such as semaglutide, then you’ve likely experienced the powerful effects of this weight loss ...
BioSpace1d
Novo’s Semaglutide Shows Promise for Alcohol Use Disorder
The data, published in JAMA Psychiatry, add to the growing body of evidence supporting the use of GLP-1 receptor agonists for ...
healthday1h
Many With Overweight, Obesity Discontinue GLP-1 Receptor Agonists Within One Year
Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within o ...
Medical News Today4d
Review links 3 potentially-blinding eye conditions to GLP-1 drugs like Ozempic
A new review reports that nine people taking semaglutide and tirzepatide — the active ingredient in GLP-1 medications — ...
News Medical4d
What's Next for Semaglutide? Beyond Diabetes and Weight Loss
Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...
Fierce Healthcare1d
Primary care doctors concerned about telehealth GLP-1 boom: survey
As demand remains high for GLP-1 drugs, primary care physicians are concerned about the risks of patients using third-party ...
How The Democratization Of GLP-1s Might Redefine Standards And Status
It’s obvious these drugs are trimming waistlines across the nation; what may be less obvious is that they might also reshape ...
Medscape1d
Study Finds Websites Aren’t Always Transparent About Compounded GLP-1 RAs
A recent study found that over a third of websites selling compounded diabetes and weight loss medications, such as Ozempic and Wegovy, falsely claim they are FDA-approved.